Pieris Pharmaceuticals (PIRS) PT Set at $12.00 by HC Wainwright
HC Wainwright set a $12.00 price objective on Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other analysts also recently issued reports on the company. BidaskClub raised Pieris Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Monday, February 5th. ValuEngine raised Pieris Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, February 2nd. Finally, William Blair began coverage on Pieris Pharmaceuticals in a research note on Wednesday, January 17th. They issued an outperform rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Pieris Pharmaceuticals has an average rating of Buy and an average price target of $10.00.
Shares of Pieris Pharmaceuticals (PIRS) opened at $8.59 on Friday. Pieris Pharmaceuticals has a 12 month low of $1.88 and a 12 month high of $8.79. The stock has a market capitalization of $320.28, a P/E ratio of -11.61 and a beta of 1.57.
In other news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.05% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PIRS. State Street Corp bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $2,377,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Pieris Pharmaceuticals during the 4th quarter valued at approximately $3,370,000. Northern Trust Corp bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $1,625,000. TIAA CREF Investment Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $649,000. Finally, Vanguard Group Inc. bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $526,000. 50.78% of the stock is currently owned by hedge funds and other institutional investors.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.